Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma

Inclusion criteria: * Recurrent glioblastoma at least 2 cm in diameter after standard treatment (Surgery, Radiotherapy and Chemotherapy), which has to be completed at least three weeks earlier. * \> 18 years of age, KPS 70-100% * No liver disease, no malignancies (except curative treated skin tumors, DCIS of the breast and curative treated cervix carcinoma) * Lc \> 3000 und Tc \> 100 000, Hb\> 9, Bilirubin \</= 1.5mg/dl, AST/ALT less than 2.5 x upper limit, creatinine \</= 132umol/l * No pregnancy or breast feeding * Written Informed Consent prior to study entry * No reasons for incompliance * Reoperation planned Exclusion criteria: * KPS \< 70% * Radiotherapy- or Chemotherapy within 6 weeks * Enzyme inducing medication or St John's wort * Other study medication within 28 days * Other malignancies * Intolerance of Patupilone * Prior Patupilone * Neuropathy \> Grad 1 * Other life threatening illnesses * Acute or chronic liver diseases * HIV Infection * Known non-compliance in medication intake,inability to give informed consent * Cardiac problems (NYHA III oder IV) with uncontrolled insufficiency or angina pectoris * Active or uncontrolled infection * Pregnancy or breast feeding * Hematologic Growth Factors (without Erythropoetin) colostomy * Patients with uncontrolled diarrhea in the last 7 days prior to study entry.